For research use only. Not for use in diagnostic procedures.
This application note demonstrates how these compounds can be separated, without compromising throughput, using Waters CORTECS UPLC Technology combined with negative mode electrospray ionization mass spectrometry.
A rapid UPLC-MS/MS methodology has been developed for the analysis of bile acids. This research method has been demonstrated to be suitable for the analysis of physiologically relevant levels of these analytes in human serum. This method utilizes a generic LC-MS platform that can be used for various compound classes (including metabolomics, lipidomics, and proteomics), meaning it can be applied as part of a suite of analyses that are run subsequently as part of a targeted multi-omics workflow.
Bile acids are an important class of biological molecules that are generated in the liver and play a central role in various biological functions, including cholesterol homeostasis. Quantitative analysis for research of bile acids using LC-MS is complicated by the presence of many isomeric compounds. Historically, this has meant that throughput has been compromised in order to separate these isomeric compounds. Here we demonstrate how these compounds can be separated, without compromising throughput, using Waters CORTECS UPLC Technology combined with negative mode electrospray ionization mass spectrometry. This application note is also part of a MetaboQuan-R method package.
100 µL of human serum was protein precipitated with 400 µL of methanol and centrifuged for three minutes at 25,000 g. 100 µL of the resulting supernatant was diluted with 100 µL of deionized water and mixed. 10 µL of this was then injected onto the UPLC-MS/MS system.
UPLC separation was performed with an ACQUITY UPLC I-Class System (fixed loop), equipped with a CORTECS T3, 2.7 µm (2.1 × 30 mm) analytical column. 10 µL of sample was injected at a flow rate of 1.3mL/min. Mobile phase A was 0.01% formic acid (aq) containing 0.2 mM Ammonium Formate and mobile phase B was 50% isopropanol in acetonitrile containing 0.01% formic acid and 0.2 mM Ammonium Formate. After an initial 0.1 minute hold at 20% Mobile phase B, the bile acids were eluted from the column and separated with a gradient of 20–55% Mobile phase B over 0.7 minutes, followed by a 0.9 minute column wash at 98% Mobile phase B. The column was then re-equilibrated to initial conditions. The analytical column temperature was maintained at 60 °C.
Multiple Reaction Monitoring (MRM) analyses were performed using a Xevo TQ-S micro MassSpectrometer. All experiments were performed in negative electrospray ionization (ESI-) mode. The ion source temperature and capillary voltage were kept constant and set to 150 °C and 2.0 kV respectively. The cone gas flow rate was 50 L/hr and desolvation temperature was 650 °C.
Method information was imported onto the LC-MS system using the Quanpedia functionality within MassLynx. This extendable and searchable database produces LC and MS methods as well as processing methods for use in TargetLynx for compound quantification.
The 16 bile acids detailed in Table 1 were separated and detected using the LC-MS platform and extraction protocol described. Some of these compounds give peaks in their MRM trace that are unidentified. These are most probably due to isomeric forms of these analytes. Figures 1 shows an example chromatogram for the separation achieved using the UPLC method detailed above. Quantitative analysis was performed for chenodeoxycholic acid in human serum by standard addition. This data is shown in Figure 2 and demonstrates the separation of chenodeoxycholic acid from deoxycholic acid. This data also shows that the limits of detection for these analytes are in the low ng/mL range.
A rapid UPLC-MS/MS methodology has been developed for the analysis of bile acids. This research method has been demonstrated to be suitable for the analysis of physiologically relevant levels of these analytes in human serum. This method utilizes a generic LC-MS platform that can be used for various compound classes (including metabolomics, lipidomics, and proteomics), meaning it can be applied as part of a suite of analyses that are run subsequently as part of a targeted multi-omics workflow.
720006261, August 2018